Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01703949
Recruitment Status : Recruiting
First Posted : October 11, 2012
Last Update Posted : November 6, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Washington

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 15, 2021
  Study Completion Date : No date given